HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Heat-shock treatment-mediated increase in transduction by recombinant adeno-associated virus 2 vectors is independent of the cellular heat-shock protein 90.

Abstract
Recombinant adeno-associated virus 2 (AAV) vectors transduction efficiency varies greatly in different cell types. We have described that a cellular protein, FKBP52, in its phosphorylated form interacts with the D-sequence in the viral inverted terminal repeat, inhibits viral second strand DNA synthesis, and limits transgene expression. Here we investigated the role of cellular heat-shock protein 90 (HSP90) in AAV transduction because FKBP52 forms a complex with HSP90, and because heat-shock treatment augments AAV transduction efficiency. Heat-shock treatment of HeLa cells resulted in tyrosine dephosphorylation of FKBP52, led to stabilization of the FKBP52-HSP90 complex, and resulted in approximately 6-fold increase in AAV transduction. However, when HeLa cells were pre-treated with tyrphostin 23, a specific inhibitor of cellular epidermal growth factor receptor tyrosine kinase, which phosphorylates FKBP52 at tyrosine residues, heat-shock treatment resulted in a further 18-fold increase in AAV transduction. HSP90 was shown to be a part of the FKBP52-AAV D-sequence complex, but HSP90 by itself did not bind to the D-sequence. Geldanamycin treatment, which disrupts the HSP90-FKBP52 complex, resulted in >22-fold increase in AAV transduction in heat-shock-treated cells compared with heat shock alone. Deliberate overexpression of the human HSP90 gene resulted in a significant decrease in AAV-mediated transduction in tyrphostin 23-treated cells, whereas down-modulation of HSP90 levels led to a decrease in HSP90-FKBP52-AAV D-sequence complex formation, resulting in a significant increase in AAV transduction following pre-treatment with tyrphostin 23. These studies suggest that the observed increase in AAV transduction efficiency following heat-shock treatment is unlikely to be mediated by HSP90 alone and that increased levels of HSP90, in the absence of heat shock, facilitate binding of FKBP52 to the AAV D-sequence, thereby leading to inhibition of AAV-mediated transgene expression. These studies have implications in the optimal use of recombinant AAV vectors in human gene therapy.
AuthorsLi Zhong, Keyun Qing, Yue Si, Linyuan Chen, Mengqun Tan, Arun Srivastava
JournalThe Journal of biological chemistry (J Biol Chem) Vol. 279 Issue 13 Pg. 12714-23 (Mar 26 2004) ISSN: 0021-9258 [Print] United States
PMID14711833 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Benzoquinones
  • DNA, Complementary
  • HSP90 Heat-Shock Proteins
  • Lactams, Macrocyclic
  • Oligonucleotides, Antisense
  • Quinones
  • Tyrphostins
  • Tyrosine
  • ErbB Receptors
  • Tacrolimus Binding Proteins
  • tacrolimus binding protein 4
  • tyrphostin A23
  • geldanamycin
Topics
  • Benzoquinones
  • Blotting, Western
  • DNA Replication
  • DNA, Complementary (metabolism)
  • Dependovirus (genetics)
  • Down-Regulation
  • Electrophoresis, Polyacrylamide Gel
  • ErbB Receptors (metabolism)
  • Genes, Viral
  • Genetic Therapy
  • HSP90 Heat-Shock Proteins (metabolism)
  • HeLa Cells
  • Humans
  • Lactams, Macrocyclic
  • Models, Biological
  • Oligonucleotides, Antisense (chemistry)
  • Phosphorylation
  • Plasmids (metabolism)
  • Precipitin Tests
  • Protein Binding
  • Quinones (pharmacology)
  • Tacrolimus Binding Proteins (chemistry)
  • Transfection
  • Transgenes
  • Tyrosine (metabolism)
  • Tyrphostins (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: